Maximizing Patient Outcomes and Minimizing Morbidity in Gastrointestinal Cancer (PRO 09)
This session focuses on the multidisciplinary care of the gastroesophageal junction, pancreatic and rectal cancer to enable the radiation oncologist and the patient to work together to make decisions on treatment, based on clinical evidence that balances risks and expected outcomes in keeping with the Pay It Forward, Partnering With Our Patients theme. Specifically, speakers will address patient selection, workup, key elements and clinical issues involved in treatment planning, and discuss challenges setting up and getting patients through treatment. The session will also cover follow-up evaluation for response and minimizing morbidity for these common gastrointestinal cancers.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, and physicists.
Upon completion of this activity, participants should be able to do the following:
- Optimize radiation techniques and plans for esophagogastric, borderline resectable pancreatic and rectal cancer.
- Assess updated dose limits to critical structures to minimize long term morbidity.
Najeeb Mohideen, MD, FASTRO, is employed by Northwest Community Hospital. He is President of the Radiosurgery Society.
Edward Y. Kim, MD, is employed by the University of Washington/Fred Hutchinson Cancer Center. He is a member of the soft tissue sarcoma panel of the National Comprehensive Cancer Network.
Krishan R. Jethwa, MD, is employed by the Mayo Clinic. Dr. Jethwa receives honoraria as the GI disease site editor for RadOncQuestions.com, LLC.
Erqi Pollom, MD, MS, is employed by the Stanford Cancer Institute, Stanford University. Dr. Pollom receives compensation from Vysioneer and GT Medical Technologies, and honoraria from Varian.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.